Boehringer Ingelheim (BI) and Bioharmony Therapeutics Collaborates to Develop Bacteriophage Lysins

 Boehringer Ingelheim (BI) and Bioharmony Therapeutics Collaborates to Develop Bacteriophage Lysins

Boehringer Ingelheim (BI) and Bioharmony Therapeutics Collaborates to Develop Bacteriophage Lysins

Shots:
  • BI to get rights to develop and commercialize bacteriophage lysins using Bioharmony ‘s technology for multi-drug resistant (MDR) Acinetobacter infections caused by Acinetobacter baumannii
  • The focus of the collaboration is to develop anti-microbial therapies against multi-drug resistant bacterial infections
  • Lysins are enzymes made of bacteriophages involved in breaching the bacterial cell wall in seconds, further killing the targeted bacteria
Click here to read full press release/ article | Ref: Businesswire | Image: BigChem

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post